IASLC names Elsevier new publisher of the Journal of Thoracic Oncology

October 14, 2015

DENVER, Colo., and AMSTERDAM, The Netherlands - The International Association for the Study of Lung Cancer (IASLC), the world's largest organization dedicated solely to the study of lung cancer, and Elsevier, a world-leading provider of scientific, technical, and medical information products and services, jointly announce Elsevier's appointment as publisher of the IASLC's official journal, Journal of Thoracic Oncology (JTO), beginning January 2016.

Published since 2006, the Journal of Thoracic Oncology emphasizes a multidisciplinary approach including original research (clinical trials and translational or basic research), reviews, and opinion pieces. This peer-reviewed journal is the primary educational and informational publication for topics relevant to detection, prevention, diagnosis, and treatment of thoracic malignancies. It has a global author base and readership comprised of epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonary specialists, radiologists, pathologists, and research scientists with a special interest in thoracic oncology.

"The IASLC is very excited by the development of the JTO and to bring the journal to the next level through our partnership with Elsevier. Through this partnership, we are looking forward to leveraging Elsevier's technical developments and the synergy with Elsevier's portfolio of other oncology journals," said Dr. Fred R. Hirsch, Professor of Medicine and Pathology at the University of Colorado Cancer Center and School of Medicine, and CEO of the IASLC.

"As the leading international lung cancer association, the IASLC is excited to expand the reach of the JTO and to ensure that medical professionals around the world have access to the cutting edge research being shared in the publication," said Alex A. Adjei, MD, PhD, Editor-in-Chief of the JTO. "We are working closely with the Elsevier team to maximize the benefits that Elsevier can provide to authors and readers of the JTO. This will allow us to take advantage of synergies with Elsevier's extensive catalog of leading cancer publications."

Researchers, academic physicians, clinicians, and the libraries that serve them will have increased access to cutting-edge research through Elsevier's sophisticated online channels, which offer readers enhanced features and expanded discoverability, while authors benefit from seamless and easy dissemination of their important work.

"We are extremely proud to have secured the opportunity to add this flagship title to our oncology journal portfolio," commented Anne Kitson, Executive Vice President, Health and Medical Sciences at Elsevier. "We look forward to working in partnership with the IASLC and the JTO to enhance the journal's reputation and influence, as well as expand its already impressive global communities of contributors and readers. We recognize the vital role that this publication plays in driving critical research forward and supporting the delivery of optimal patient care."

With a significant Impact Factor of 5.282, JTO is ranked 30th out of 211 journals in Oncology and 7th out of 57 journals in Respiratory Medicine*. Managing Editor Mary Sharkey Todd will continue to provide support and guidance to the JTO and IASLC community.
*2014 Journal Citation Reports®, Thomson Reuters, 2015

Elsevier Health Sciences

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.